{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-036816","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.449759+00:00","generated_at":"2026-05-26T03:25:51.340956+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Catalyst Pharma reports FY2024 revenue $491.7M (+23.5% YoY), guides FY2025 $545-565M","bullets":["Q4 net product revenue $141.8M; full-year FIRDAPSE revenue $306M (+18.4%), AGAMREE $46M (new launch).","GAAP net income $163.9M ($1.31 diluted EPS) vs $71.4M ($0.63) in 2023; non-GAAP net income $276.3M ($2.21 diluted EPS).","Cash and equivalents $517.6M at year-end, up 276% from $137.6M a year ago.","Full year 2025 revenue guidance set at $545-565M, reflecting continued growth momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-036816","json":"https://secwatch.observer/filing/0001193125-25-036816.json","markdown":"https://secwatch.observer/filing/0001193125-25-036816.md","text":"https://secwatch.observer/filing/0001193125-25-036816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525036816/0001193125-25-036816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525036816/d861503d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:25:51.340956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}